Dr Jean-Charles Duclos-Vallée and team from France found Liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus is a recent indication.
The team have compared the survival and severity of recurrent Hepatitis C virus infection after liver transplantation in human immunodeficiency virus-HCV-coinfected and hepatitis C virus-monoinfected patients.
The team evaluated 79 patients receiving a first liver graft for Hepatitis C virus-related liver disease between 1999 and 2005.
|2-year survival rates were 73% in co-infected patients|
The team found among them, 35 had highly active antiretroviral therapy-controlled human immunodeficiency virus infection.
All patients were monitored for Hepatitis C virus viral load and liver histology during the posttransplantation course.
The team found coinfected patients were younger, and had a higher Model for End-Stage Liver Disease score.
The researchers noted that the 2-year and 5-year survival rates were 73% and 51%, in coinfected patients, respectively.
The research team observed that the 2-year and 5-year survival rates were 91% and 81% in monoinfected patients, respectively.
Under multivariate Cox analysis, survival was related only to the Model for End-Stage Liver Disease score.
Using the Kaplan-Meier method, the progression to fibrosis F2 was significantly higher in the coinfected group.
Dr Duclos-Vallée's team concluded, "The results of liver transplantation in human immunodeficiency virus-Hepatitis C virus-coinfected patients were satisfactory in terms of survival benefit."
"Earlier referral of these patients to a liver transplant unit, the use of new drugs effective against Hepatitis C virus, and an avoidance of drug toxicity are mandatory if we are to improve the results of this challenging indication for liver transplantation."